Aarti Pharmalabs Ltd.
Fundamentals
- Market cap
- ₹6,262 cr
- P/E
- 35.84×
- ROE
- 13.69%
- Debt / equity
- 0.20
- Div yield
- 0.49%
- 52-week range
- 585.00 — 971.00
Company snapshot
Aarti Pharmalabs Ltd.
CDMO
₹6,403 cr
P/E 36.65×
Latest quarter · Mar 2026
Sales₹583 cr
Net profit₹56 cr
Op. margin+19.4%
EPS₹6.74
Strength & growth
Debt / equity0.20×
Current ratio2.01×
The timeline — 4 notes on Aarti Pharmalabs Ltd.
May 2026
- 26 May 26 · 5:28 PM IST Brief Brief · Earnings · Mid cap
Aarti Pharmalabs targets 40-50% CDMO growth as project pipeline shrinks
Management expects long-term revenue growth of 15-18% but faces near-term margin pressure from startup costs and raw material inflation.
- 26 May 26 · 1:25 PM IST Brief Brief · Earnings · Mid cap
Aarti Pharmalabs profit drops as finance costs and margins bite
The pharmaceutical firm reported a decline in annual profit to ₹176.20 crore, down from ₹238.03 crore in the previous year.
- 25 May 26 · 9:16 PM IST Brief Brief · Earnings · Mid cap
Aarti Pharmalabs profit slides as costs and forex losses mount
Standalone net profit fell to ₹62.03 crore in Q4, down from ₹88.85 crore a year ago, as finance costs and currency headwinds pressured margins.
- 25 May 26 · 9:09 PM IST Brief Brief · Earnings · Mid cap
Aarti Pharmalabs profit drops as derivative accounting error surfaces
Standalone net profit fell to ₹62.03 crore in Q4, while the company disclosed a ₹29.73 crore loss from a previously omitted derivative contract.